{"id":1963,"date":"1998-05-01T12:09:00","date_gmt":"1998-05-01T10:09:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/leserbrief-extrem-unterschiedliche-preise-von-cabergolin"},"modified":"1998-05-01T12:09:00","modified_gmt":"1998-05-01T10:09:00","slug":"leserbrief-extrem-unterschiedliche-preise-von-cabergolin","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/leserbrief-extrem-unterschiedliche-preise-von-cabergolin","title":{"rendered":"Leserbrief: Extrem unterschiedliche Preise von Cabergolin"},"content":{"rendered":"<p>Ein Neurologe aus Hessen teilt uns zu unserem Artikel zur Therapie des Prolaktinoms mit Dopamin-Agonisten (AMB 1998, 32, 22b) mit, da\u00df der dort erw\u00e4hnte neue und teure Dopamin-Agonist Cabergolin (Dostinex, Fa. Pharmacia &#038; Upjohn), der f\u00fcr die Indikationen Abstillen und Prolaktinom-Behandlung angeboten wird, auch noch unter einem zweiten Namen (Cabaseril, ebenfalls von Fa. Pharmacia &#038; [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ein Neurologe aus Hessen teilt uns zu unserem Artikel zur Therapie des Prolaktinoms mit Dopamin-Agonisten (AMB 1998, 32, 22b) mit, da\u00df der dort erw\u00e4hnte neue und teure Dopamin-Agonist Cabergolin (Dostinex, Fa. Pharmacia &#038; Upjohn), der f\u00fcr die Indikationen Abstillen und Prolaktinom-Behandlung angeboten wird, auch noch unter einem zweiten Namen (Cabaseril, ebenfalls von Fa. Pharmacia &#038; [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1661,1660],"class_list":["post-1963","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-cabergolin","tag-dopamin-agonisten"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1963","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1963"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1963\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}